Bristol R&D In Brief

Bristol Glucophage exclusivity: Bristol is unable to give 2002 guidance due to uncertainty surrounding Glucophage exclusivity, CEO Peter Dolan told a Nov. 7 update on the company's R&D program. "As this could be a meaningful contributor to our sales and earnings and because we maintain that our pediatric label legally entitles us an additional three years of exclusivity, any statements or stated assumptions about 2002 for the Glucophage family...could jeopardize this rapidly evolving situation." Bristol "appears to be close to knowing whether there'll be legislation affecting our rights...and what the FDA will be doing"...